Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Subcutaneous Depot Medroxyprogesterone Acetate Self-Administration

Contraception; ePub 2016 Jun 17; Upadhyay, et al

Women who have recently had an abortion, those reporting difficulty returning to a family planning provider, and current depot medroxyprogesterone acetate (DMPA) users showed substantial interest in self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC), according to a recent study. Survey data on contraceptive attitudes from 1,592 women in the US collected from March to July 2011 revealed:

• 21% of women reported interest in self-administration.

• Women currently using DMPA (aOR, 3.93) and women who previously used DMPA (aOR, 1.71) were more likely to have an interest in DMPA-SC compared to those who never used it.

• Women who reported having difficulty obtaining or filling a prescription were nearly twice as likely to have interest in DMPA-SC as women who reported no difficulty.

• Women surveyed at abortion sites were more likely to report interest in self-administration vs women surveyed at family planning sites.

• A desire to eliminate unnecessary return visits to a facility for repeat injections was the primary reason for interest in DMPA-SC.

Citation: Upadhyay UD, Zidar VM, Foster DG. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States. [Published online ahead of print June 17, 2016]. Contraception. doi:10.1016/j.contraception.2016.06.006.